OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed a late-stage study in patients with advanced prostate cancer.

More on this...

The drug, custirsen, was being tested in certain prostate cancer patients whose disease progressed despite chemotherapy treatment.